Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer.
BACKGROUND:Personalized treatment for cancer patients is a hot topic of debate, particularly the decision to initiate chemotherapy in patients with Estrogen receptor (ER)-positive, HER2-negative tumors in the early stages of breast cancer (BC). Owing to significant advancements in information techno...
Main Authors: | Yun Yeong Kim, Se Jeong Oh, Yong Soon Chun, Woon Kee Lee, Heung Kyu Park |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC6034851?pdf=render |
Similar Items
-
Adequacy and Effectiveness of Watson For Oncology in the Treatment of Thyroid Carcinoma
by: Hyeok Jun Yun, et al.
Published: (2021-03-01) -
Early experience with Watson for oncology in Korean patients with colorectal cancer.
by: Eui Joo Kim, et al.
Published: (2019-01-01) -
A meta-analysis of Watson for Oncology in clinical application
by: Zhou Jie, et al.
Published: (2021-03-01) -
Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
by: Sung Gwe Ahn, et al.
Published: (2018-03-01) -
Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay.
by: Sung Gwe Ahn, et al.
Published: (2017-01-01)